Status: Recruiting
A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)
This is a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.
Participants needed: 210
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Hyundai Bioscience Co., Ltd.Updated: May 8, 2026Locations: 2
Eligibility criteria
Patients who are 18 years or over of age at time of screening. [+2]
Patients who show severe dengue (WHO dengue guideline C, any severe symptoms or... [+2]